Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial | BioPharma Dive

Retrieved on: 2021-09-09 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial | BioPharma Dive. View article details on hiswai:

Excerpt

Sanofi is competing with Merck KGaA and Roche to bring a drug from ... of Merck KGaA's evobrutinib and Roche's fenebrutinib, in 2023 and 2024.

Article found on: www.biopharmadive.com